SANTA BARBARA, Calif., Feb. 07, 2017 -- Sientra, Inc. (NASDAQ:SIEN), a medical aesthetics company, today announced the appointment of aesthetics industry veteran executive Dr. Philippe A. Schaison to the Company’s board of directors, effective February 6, 2017.
Jeffrey M. Nugent, Chairman and Chief Executive Officer of Sientra, said, “As one of the premier leaders of the global aesthetics industry, I have known Philippe for some time and I am confident that he will bring a unique perspective and will add to our board’s deep focus on this category. We believe his experience and insight in building, acquiring, growing, and leading world class aesthetic products and brands will be instrumental to the growth of our business. His appointment comes at a critical juncture for Sientra, as we continue to make progress toward comprehensive manufacturing supply and on our longer-term objective of becoming a world class, diversified aesthetics organization.”
Dr. Schaison has extensive experience leading global aesthetic organizations. In November, 2016, Dr. Schaison joined Syneron Medical Ltd., (NASDAQ:ELOS), a leading global aesthetic device company, and currently serves as CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Previously, Dr. Schaison served as President of Allergan’s U.S. aesthetic and dermatology business. In that position, he led the Facial Aesthetic, Plastic and MedDerm/Skin Medical business unit, an organization of over 2,000 professionals focused on the company’s Botox® and fillers franchises.
Prior to joining Allergan, Dr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York. Earlier, Dr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines and as Vice President of Global Skin Care for Johnson & Johnson, with P&L responsibility for Aveeno, Clean & Clear, Lubriderm, and Ambi, and in executive positions at L'Oréal. Dr. Schaison sits on the Board of the Galien Foundation and SENTÉ, Inc., a privately held specialty aesthetics company. He earned his MBA (Marketing) from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company committed to making a difference in patients’ lives by enhancing their body image, growing their self-esteem and restoring their confidence. The Company was founded to provide greater choice to board-certified plastic surgeons and patients in need of medical aesthetics products. The Company has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants and breast tissue expanders exclusively to board-certified and board-admissible plastic surgeons and tailors its customer service offerings to their specific needs. The Company also offers a range of other aesthetic and specialty products including bioCorneum®, the professional choice in scar management.
Forward-looking statements
Any forward-looking statements are subject to risks and uncertainties such as those described in Sientra’s most recently filed Quarterly Report on Form 10-Q and and its Annual Report on Form 10-K for the year ended December 31, 2015 which Sientra filed with the Securities and Exchange Commission on March 10, 2016. Actual results may differ materially from anticipated results.
Investor Contacts: Patrick F. Williams Sientra, Chief Financial Officer (619) 675-1047 [email protected] Nick Laudico / Brian Johnston The Ruth Group (646) 536-7030 / (646) 536-7028 [email protected]


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Italy Fines Apple €98.6 Million Over App Store Dominance
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 



